US20060083731A1 - Use of an enzyme for the manufacture of an agent for controlling bacterial infection - Google Patents
Use of an enzyme for the manufacture of an agent for controlling bacterial infection Download PDFInfo
- Publication number
- US20060083731A1 US20060083731A1 US11/289,364 US28936405A US2006083731A1 US 20060083731 A1 US20060083731 A1 US 20060083731A1 US 28936405 A US28936405 A US 28936405A US 2006083731 A1 US2006083731 A1 US 2006083731A1
- Authority
- US
- United States
- Prior art keywords
- cellulase
- bacterial infection
- diet
- chickens
- campylobacter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000035143 Bacterial infection Diseases 0.000 title claims abstract description 27
- 208000022362 bacterial infectious disease Diseases 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title abstract description 8
- 102000004190 Enzymes Human genes 0.000 title description 21
- 108090000790 Enzymes Proteins 0.000 title description 21
- 235000005911 diet Nutrition 0.000 claims abstract description 58
- 230000037213 diet Effects 0.000 claims abstract description 58
- 241001465754 Metazoa Species 0.000 claims abstract description 39
- 235000021307 Triticum Nutrition 0.000 claims abstract description 34
- 241000287828 Gallus gallus Species 0.000 claims abstract description 30
- 241000589876 Campylobacter Species 0.000 claims abstract description 29
- 235000013330 chicken meat Nutrition 0.000 claims abstract description 28
- 108010059892 Cellulase Proteins 0.000 claims abstract description 23
- 229940106157 cellulase Drugs 0.000 claims abstract description 22
- 241000607142 Salmonella Species 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 241000193468 Clostridium perfringens Species 0.000 claims abstract description 10
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 241000209140 Triticum Species 0.000 claims abstract 7
- 238000000034 method Methods 0.000 claims description 26
- 241000894006 Bacteria Species 0.000 claims description 21
- 235000013339 cereals Nutrition 0.000 claims description 15
- 240000008042 Zea mays Species 0.000 claims description 11
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 11
- 235000009973 maize Nutrition 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 6
- 101710130006 Beta-glucanase Proteins 0.000 claims description 5
- 240000005979 Hordeum vulgare Species 0.000 claims description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000003307 slaughter Methods 0.000 claims description 4
- 235000007319 Avena orientalis Nutrition 0.000 claims description 3
- 244000075850 Avena orientalis Species 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 241000209056 Secale Species 0.000 claims description 3
- 235000007238 Secale cereale Nutrition 0.000 claims description 3
- 240000006394 Sorghum bicolor Species 0.000 claims description 3
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 3
- 235000019714 Triticale Nutrition 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 241000228158 x Triticosecale Species 0.000 claims description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 abstract description 28
- 239000003242 anti bacterial agent Substances 0.000 abstract description 15
- 229940088710 antibiotic agent Drugs 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 6
- 230000007613 environmental effect Effects 0.000 abstract description 5
- 244000098338 Triticum aestivum Species 0.000 description 28
- 229940088598 enzyme Drugs 0.000 description 18
- 244000144992 flock Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 239000004365 Protease Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920001221 xylan Polymers 0.000 description 4
- 150000004823 xylans Chemical class 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 3
- 241000589875 Campylobacter jejuni Species 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 206010048282 zoonosis Diseases 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 description 2
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 2
- 244000188595 Brassica sinapistrum Species 0.000 description 2
- 208000003495 Coccidiosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 239000004470 DL Methionine Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010023076 Isosporiasis Diseases 0.000 description 2
- 235000019738 Limestone Nutrition 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 244000000074 intestinal pathogen Species 0.000 description 2
- 239000006028 limestone Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 206010051226 Campylobacter infection Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000223198 Humicola Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 241000233892 Neocallimastix Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 235000019779 Rapeseed Meal Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000223262 Trichoderma longibrachiatum Species 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 244000309146 drought grass Species 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 108010003007 mannose isomerase Proteins 0.000 description 1
- -1 mannose polysaccharides Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000004456 rapeseed meal Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention is directed to the use of an enzyme for the manufacture of an agent for the treatment and/or prophylaxis of a bacterial infection.
- the domestic animal of particular, but not exclusive, concern with regard to zoonosis is the chicken. Campylobacter and Salmonella are particularly prevalent in the chicken.
- the bacteria are transmitted to the bird in a variety of ways, including through feed, water, litter and vermin.
- the bacteria initially infect the caecae of the chicken.
- the disease then progresses to the small intestine where infestation may cause loss of weight in the bird.
- a particular problem with the chicken is that it is almost impossible to eviscerate in a sterile manner with the result that bacteria inhabiting the intestines will invariably be transmitted to the saleable carcass. Accordingly the potential for zoonosis is great, unless the carcass is handled or cooked properly.
- the cost of human infection caused by eating improperly treated chicken is significant in terms of both time and lives.
- JP-A-81-73055 discloses animal feeds intended to prevent contamination with Salmonella.
- the feeds are indicated to contain partially decomposed mannan in the form of mannose polysaccharides. These are produced by degradation of mannan with an enzyme, produced by micro-organisms.
- the resulting feed was found to be moderately effective against Salmonella in chickens, but is not effective against Campylobacter.
- U.S. Pat. No. 5,124,262 discloses a mannose isomerase enzyme used for converting fructose to mannose. The mannose thus produced is taught to be useful in feeds, for inhibiting the growth of Salmonella in chickens.
- xylan prepared from steamed bamboo grass is mentioned as inhibiting the growth of various human intestinal bacteria.
- the xylan is indicated to be effective against Salmonella.
- the inhibition effect is reversed after a period of 24 hours.
- WO 93/01800 discloses the use of a protease for the preparation of a medicament effective against intestinal pathogens in animals.
- the pathogens of interest include Campylobacter.
- enzymes other than proteases being useful in controlling animal pathogens.
- EP-A-0 681 787 discloses use of a carbohydrase or protease for the manufacture of an agent for the treatment of Coccidiosis.
- Coccidiosis in chickens is caused by protozoal oocytes.
- the document does not indicate how bacterial pathogens in chickens, or other animals, can be controlled.
- one object of the present invention is to provide an agent which can be used for controlling bacterial infection that is more effective than the presently available agents, and in particular than those described in the prior art acknowledged above.
- a further object of the present invention is to provide an agent which can be used for controlling bacterial infection that is less harmful to the environment, less expensive than the presently available agents, and has advantages for human health.
- the present invention provides the use of a xylanase or a cellulase for the manufacture of an agent for the treatment and/or prophylaxis of bacterial infection in an animal caused by Salmonella, Campylobacter or Clostridium perfringens.
- a preferred cellulase is ⁇ -glucanase.
- FIG. 1 shows the effect of three diets on Campylobacter colonisation in 12-day old chicks. Three different dilution levels of the initial stock solution of Campylobacter were used to introduce the pathogen to the chicks. The results are presented as mean scores of positive caecae and represent the combined results of two flocks A and B comprising a total of 108 birds (12 per dilution for each of the three diets);
- FIG. 2 shows the results of FIG. 1 , but for flock A alone;
- FIG. 3 shows the results of FIG. 1 , but for flock B alone;
- FIG. 4 shows similar results to FIG. 1 , but at three alternative dilution levels of the initial Campylobacter stock solution. The results are presented as mean counts log 10 CFU(Colony Forming Units)/ml;
- FIG. 5 shows the results of FIG. 4 , but for flock A alone
- FIG. 6 shows the results of FIG. 4 , but for flock B alone
- FIG. 7 shows the effect of three diets on Campylobacter colonisation of the small intestine and caecae of 17-day old chicks.
- the results are presented as mean counts log 10 CFU/ml, and represent the combined results of two flocks A and B comprising a total of 72 birds (12 per treatment) for each of the three diets;
- FIG. 8 shows the results of FIG. 7 , but for flock A alone
- FIG. 9 shows the results of FIG. 7 , but for flock B alone
- FIG. 10 shows a comparison of the weight of 1, 5, 12, 19, 25 and 33-day old chicks (20 in total) dosed with Campylobacter jejuni, and similar chicks (25 in total) which have not been dosed, the chicks all being fed a wheat-based diet;
- FIG. 11 shows similar results to those of FIG. 10 , but for chicks on a wheat plus xylanase diet;
- FIG. 12 shows similar results to those of FIG. 10 , but for chicks on a maize-based diet.
- FIG. 13 shows the effect of two different diets (wheat and wheat plus xylanase) on Salmonella enteritidis colonisation in 14 day old chicks. The results are presented as mean counts log 10 CFU/ml. Tests were carried out on two flocks, A and B, comprising a total of 48 birds, 24 per diet.
- the present invention also has benefits for human health. Its use reduces the selection pressure for antibiotic-resistant strains of bacteria, by allowing antibiotics to be removed from animal feed. Accordingly, more antibiotic-susceptible strains will be present in the gut of the animal, thereby ensuring a more likely positive outcome in the event of antibiotics being used on the equivalent human condition.
- the xylanase or cellulase enzyme to be used in the feeds can be formulated as a pre-mix together with any other enzymes to be included.
- the pre-mix can be added to the raw materials before feed manufacture, during feed manufacture or as a final step once the feed is otherwise ready for use. It is possible to add the enzyme directly as a liquid to a feed material pre-formed as pellets or as a mash.
- the enzyme in the animal's diet by incorporating it into a second (and different) feed or drinking water which the animal also has access to. Accordingly, it is not essential that the enzyme is incorporated into the feed itself, although such incorporation forms a particularly preferred aspect of the present invention.
- the enzyme is incorporated into a feed, then this preferably comprises at least 25% by weight of a cereal, and more preferably at least 35% by weight of the cereal.
- the cereal may be any one or more of wheat, maize, rye, barley, oats, triticale, rice, and sorghum. It is particularly preferred that the cereal is wheat.
- the cereal component of a cereal-based diet constitutes a source of protein
- sources of supplementary protein such as those derived from fishmeal, meatmeal or vegetables.
- sources of supplementary protein may constitute up to 50% by weight of the animal feed.
- Sources of vegetable protein include at least one of full fat soybean, rapeseed, canola, soybean meal, rapeseed meal and canola meal.
- the enzyme is incorporated into a feed, then this is preferably added in a relative amount of 0.0001-10 g of the enzyme per kilo of the feed, more preferably 0.001-1 g/kg and most preferably 0.01-0.1 g/kg.
- the xylanase for use in this invention can be obtained from a fungus, such as Trichoderma, Aspergillus, Humicola, or Neocallimastix.
- the xylanase can be obtained from a bacterium, such as Bacillus, Streptomyces, Clostridium, or Ruminococcus.
- the present invention is particularly effective against strains of Salmonella and Campylobacter, and especially Salmonella enteritidis and Campylobacter jejuni.
- Another bacterium against which the invention is effective is Clostridium perfringens.
- Bacterial infection can be treated or prevented in accordance with the present invention in a wide variety of animals, but use of the invention is particularly preferred in domestic animals and farm livestock.
- Animals which may in particular benefit from the invention include poultry (such as chickens, turkeys, ducks and geese), ruminants (such as cattle, horses and sheep), swine (pigs), cats, dogs, rodents (such as rabbits) and fish.
- the invention is particularly useful in broiler chickens.
- feed and enzyme include wheat plus xylanase, maize plus xylanase and barley plus ⁇ -glucanase.
- the enzymes used in the present invention fall within a general Class called polysaccharidases.
- Their substrates are structural polysaccharides such as xylans and ⁇ -glucans that occur as an integral part of the cell wall of most land plants. These polysaccharides are not found in animal cells, and are not to be expected to have any activity against proteins. Because these enzymes attack polysaccharides found in plant cell walls, the only possible substrates for these enzymes in the gastrointestinal tract of an animal are contained in cereal-based feeds. It is therefore speculated that the beneficial effects of the xylanase or cellulase on bacterial infection result somehow from the degradation products which they produce such as xylan or ⁇ -glucan derived from a cereal-based diet.
- WO 93/01800 discloses the use of a protease for the preparation of a medicament effective against intestinal pathogens in animals. It is well established that such pathogens mediate their infectivity by binding to receptors on the surface of intestinal epithelial cells via antigenic protein or glycoprotein molecules expressed on the pathogen's cell surface. It is suggested that the protease enzyme prevents binding of the pathogen cells to the intestinal epithelium by destroying these proteinaceous receptor/adhesion sites to which the pathogen must bind if it is to cause an infection.
- protease ensymes mentioned in this reference would be predicted to destroy proteins on the lumenal surface of intestinal epithelial cells in a non-specific manner, but would not be expected to attack substrates other than proteins. Accordingly, the activity of the proteases disclosed in this reference is fundamentally different from the activity of the enzymes used in the present invention. A skilled person could not have predicted the utility of the present enzymes against bacterial infection based upon the activity of proteases disclosed in WO 93/01800.
- Animal feeds were prepared by introducing a cereal carrier containing approximately 3 mg enzyme protein/kg into the wheat diet at a concentration of 1 kg of enzyme and carrier per tonne of wheat diet. The final concentration of enzyme protein in the feed was thus approximately 3 mg per tonne.
- the xylanase was obtained from Trichoderma longibrachiatum. Broiler chicks were fed the wheat plus xylanase diet from hatching. For comparison purposes, separate flocks of chicks were fed with the wheat diet and the maize diet without the addition of xylanase. A challenge model was used, whereby 0.2 ml of a stock solution of C. jejuni were introduced to each chick by syringe at day 7 from hatching.
- the dilution level of the stock solution was varied, from 10 ⁇ 1 (high challenge) to 10 ⁇ 6 (low challenge, similar to natural conditions).
- the undiluted stock solution contained approximately 10 4 CFU per 0.2 ml.
- the caecae of the chicks were examined for damage due to the Campylobacter at varying ages.
- FIGS. 1-6 show the effect of the diets on Campylobacter colonisation in 12-day old chicks. In each case two flocks, A and B, were tested to minimise the effect of environmental variance on the results. In each case it is clearly evident that a wheat plus xylanase diet is effective in reducing the level of Campylobacter in the caecae of the chicks in comparison with a maize diet. Additionally, at Campylobacter stock solution dilution levels of 10 ⁇ 3 or lower (i.e. approaching more natural conditions), the wheat plus xylanase diet becomes considerably more effective than the wheat diet alone. Thus, in FIG.
- FIGS. 7-9 demonstrate the effectiveness of the diets on Campylobacter colonisation of the small intestine and caecae of 17-day old chicks from two flocks.
- the effect of the wheat plus xylanase diet on reducing the Campylobacter colonisation of the caecae of the chicks is evident as already demonstrated in Example 1. However this reduction is even more marked as regards the small intestine. Accordingly, in FIG. 7 the mean count log 10 CFU in the small intestine measured for chicks on the wheat and xylanase diet was less than 4.
- the equivalent counts for the diets not containing xylanase were found to be approximately 6, i.e. 100-fold higher.
- FIGS. 10-12 depict a comparison of the effect of different diets on the weight of 1, 5, 12, 19, 25 and 33-day old chicks.
- FIG. 10 shows the results for the wheat-based diet
- FIG. 11 the results for the wheat plus xylanase-based diet
- FIG. 12 the results for the maize-based diet.
- the weight of the chicks in each case is reduced by dosing with Campylobacter.
- those chicks to which Campylobacter has been introduced gain weight more quickly on the wheat plus xylanase diet than on either of the other diets.
- FIG. 13 demonstrates the effectiveness of the wheat and wheat plus xylanase diets on Salmonella enteritidis colonisation of the caecae of 14-day old chicks from two flocks, A and B.
- the methodology employed in these experiments was identical to that employed for the Campylobacter experiments described above, except that the undiluted stock solution of Salmonella enteritidis contained approximately 10 5 CFU per 0.2 ml.
- the effect of the wheat plus xylanase diet on reducing the Salmonella colonisation of the caecae of the chicks is clearly evident.
- flock B the chicks on the wheat diet were found to have a mean count log 10 CFU/ml of approximately 7.
- the chicks from flock B on the wheat plus xylanase diet were found to have a much lower log 10 CFU/ml of approximately 4 (1000-fold lower).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Xylanase or a cellulase for the manufacture of an agent for the treatment and/or prophylaxis of bacterial infection in an animal caused by Salmonella, Campylobacter or Clostridium perfringens. It is preferred that xylanase is used in combination with wheat to form an animal feed. Such a diet is particularly effective in controlling Campylobacter and Salmonella in chickens. The use provided by the present invention affords an alternative to antibiotics when controlling bacterial infection in animals. This leads to considerable health, environmental and economic benefits.
Description
- This application is a divisional of application Ser. No. 09/487,383, filed Jan. 18, 2000, which is a continuation of International Application No. PCT/EP98/04440, filed Jul. 16, 1998, the disclosures of which applications are incorporated by reference herein in their entireties, and which claim foreign priority of United Kingdom Application No. GB/9715214.4, filed Jul. 18, 1997.
- 1. Field of the Invention
- The present invention is directed to the use of an enzyme for the manufacture of an agent for the treatment and/or prophylaxis of a bacterial infection.
- 2. Discussion of Background Information
- The farming of many different types of animals is important throughout the world for the production of food for human consumption. When the animals are reared, they come into contact with a variety of infection-causing bacteria, such as Campylobacter and Salmonella. In some cases these bacteria may spread directly from animals to humans (zoonosis). Accordingly, it is necessary from an economic, environmental and health perspective that such bacterial infection is prevented or eradicated in the animal prior to human consumption to prevent the spread of the disease to humans.
- The domestic animal of particular, but not exclusive, concern with regard to zoonosis is the chicken. Campylobacter and Salmonella are particularly prevalent in the chicken. The bacteria are transmitted to the bird in a variety of ways, including through feed, water, litter and vermin. The bacteria initially infect the caecae of the chicken. The disease then progresses to the small intestine where infestation may cause loss of weight in the bird. A particular problem with the chicken is that it is almost impossible to eviscerate in a sterile manner with the result that bacteria inhabiting the intestines will invariably be transmitted to the saleable carcass. Accordingly the potential for zoonosis is great, unless the carcass is handled or cooked properly. The cost of human infection caused by eating improperly treated chicken is significant in terms of both time and lives.
- Accordingly, presently there is a demand for improved methods of reducing bacterial infection in animals such as the chicken, in particular those intended for human consumption.
- Various solutions to the problem of bacterial infection have been proposed. Current methods of control include the application of antibiotics, feed sterilisation and careful and controlled handling and cooking of the carcass after slaughter. Feed sterilisation has proved ineffective in the absence of a sterile rearing environment (which is impractical) whilst controlled handling and cooking cannot be relied upon in every instance. The application of antibiotics has proved unpopular with consumer groups wishing to reduce the quantity of potentially harmful chemicals in food. The use of antibiotics has the additional problem that if they are not introduced into the animal in a properly controlled manner, antibiotic-resistant strains of bacteria can be created, making such infections more difficult to treat in the future. The prophylactic use of antibiotics in animal feed has thus been regulated in some countries (notably Sweden and Finland) effectively reducing the available methods of control. Indeed no single method provides a barrier which completely prevents bacteria being transferred from the animal to humans.
- As an alternative to the above methods it has been proposed in Poultry Science, 1994 73:402-407, to introduce flora into chickens to compete with the bacteria causing the infection. Such mucosal competitive exclusion flora (MCE) were found to reduce the level of Campylobacter jejuni infection in chickens. However, the competitive exclusion treatment is not found to be consistently effective, its efficacy varying from animal to animal.
- JP-A-81-73055 discloses animal feeds intended to prevent contamination with Salmonella. The feeds are indicated to contain partially decomposed mannan in the form of mannose polysaccharides. These are produced by degradation of mannan with an enzyme, produced by micro-organisms. The resulting feed was found to be moderately effective against Salmonella in chickens, but is not effective against Campylobacter.
- U.S. Pat. No. 5,124,262 discloses a mannose isomerase enzyme used for converting fructose to mannose. The mannose thus produced is taught to be useful in feeds, for inhibiting the growth of Salmonella in chickens.
- In Bamboo J. 1993, pp. 29-35, xylan prepared from steamed bamboo grass is mentioned as inhibiting the growth of various human intestinal bacteria. In particular the xylan is indicated to be effective against Salmonella. However, the inhibition effect is reversed after a period of 24 hours.
- The above methods have proved more desirable from an environmental and health point of view, than the administration of antibiotics. However, none have proved effective enough to be commercially viable.
- WO 93/01800 discloses the use of a protease for the preparation of a medicament effective against intestinal pathogens in animals. The pathogens of interest include Campylobacter. However, there is no mention of enzymes other than proteases being useful in controlling animal pathogens.
- EP-A-0 681 787 discloses use of a carbohydrase or protease for the manufacture of an agent for the treatment of Coccidiosis. However, Coccidiosis in chickens is caused by protozoal oocytes. The document does not indicate how bacterial pathogens in chickens, or other animals, can be controlled.
- Accordingly, one object of the present invention is to provide an agent which can be used for controlling bacterial infection that is more effective than the presently available agents, and in particular than those described in the prior art acknowledged above. A further object of the present invention is to provide an agent which can be used for controlling bacterial infection that is less harmful to the environment, less expensive than the presently available agents, and has advantages for human health.
- Accordingly, the present invention provides the use of a xylanase or a cellulase for the manufacture of an agent for the treatment and/or prophylaxis of bacterial infection in an animal caused by Salmonella, Campylobacter or Clostridium perfringens.
- A preferred cellulase is β-glucanase.
-
FIG. 1 shows the effect of three diets on Campylobacter colonisation in 12-day old chicks. Three different dilution levels of the initial stock solution of Campylobacter were used to introduce the pathogen to the chicks. The results are presented as mean scores of positive caecae and represent the combined results of two flocks A and B comprising a total of 108 birds (12 per dilution for each of the three diets); -
FIG. 2 shows the results ofFIG. 1 , but for flock A alone; -
FIG. 3 shows the results ofFIG. 1 , but for flock B alone; -
FIG. 4 shows similar results toFIG. 1 , but at three alternative dilution levels of the initial Campylobacter stock solution. The results are presented as mean counts log10CFU(Colony Forming Units)/ml; -
FIG. 5 shows the results ofFIG. 4 , but for flock A alone; -
FIG. 6 shows the results ofFIG. 4 , but for flock B alone; -
FIG. 7 shows the effect of three diets on Campylobacter colonisation of the small intestine and caecae of 17-day old chicks. The results are presented as mean counts log10CFU/ml, and represent the combined results of two flocks A and B comprising a total of 72 birds (12 per treatment) for each of the three diets; -
FIG. 8 shows the results ofFIG. 7 , but for flock A alone; -
FIG. 9 shows the results ofFIG. 7 , but for flock B alone; -
FIG. 10 shows a comparison of the weight of 1, 5, 12, 19, 25 and 33-day old chicks (20 in total) dosed with Campylobacter jejuni, and similar chicks (25 in total) which have not been dosed, the chicks all being fed a wheat-based diet; -
FIG. 11 shows similar results to those ofFIG. 10 , but for chicks on a wheat plus xylanase diet; -
FIG. 12 shows similar results to those ofFIG. 10 , but for chicks on a maize-based diet; and -
FIG. 13 shows the effect of two different diets (wheat and wheat plus xylanase) on Salmonella enteritidis colonisation in 14 day old chicks. The results are presented as mean counts log10CFU/ml. Tests were carried out on two flocks, A and B, comprising a total of 48 birds, 24 per diet. - The advantage of using feeds containing a xylanase or a cellulase for rearing animals is that the amount of antimicrobial drugs which have previously been routinely incorporated into their diet can be reduced, or in some cases omitted entirely. This enables considerable economic savings to be achieved in view of the relative expense of antibiotics. In countries where such drugs are banned, it represents a totally new approach to the control of bacterial diseases.
- When omitting antibiotics from an animal's diet there are several potential further benefits. It has previously been necessary to withdraw antibiotics from the animal's diet for a certain time prior to slaughter. This ensures that the meat is relatively free from such drugs and thus fit for human consumption. In contrast, if antibiotics are entirely omitted from an animal's diet, as may be achieved with the present invention, then the animal can be slaughtered at any age rather than after a certain withdrawal period. This affords the farmer improved flexibility and removes the risk of animals becoming infected shortly prior to slaughter. Further, meat and eggs can be guaranteed free of antibiotics. Such meat and eggs have a market advantage as compared to products which cannot support such a guarantee.
- Even if the enzyme added to the animal's diet only enables the level of inclusion of antibiotics to be reduced, then the overall cost of controlling bacterial infection will be reduced. Synergy or potentiation may extend the useful life of the antibiotic.
- The present invention also has benefits for human health. Its use reduces the selection pressure for antibiotic-resistant strains of bacteria, by allowing antibiotics to be removed from animal feed. Accordingly, more antibiotic-susceptible strains will be present in the gut of the animal, thereby ensuring a more likely positive outcome in the event of antibiotics being used on the equivalent human condition.
- The xylanase or cellulase enzyme to be used in the feeds can be formulated as a pre-mix together with any other enzymes to be included. The pre-mix can be added to the raw materials before feed manufacture, during feed manufacture or as a final step once the feed is otherwise ready for use. It is possible to add the enzyme directly as a liquid to a feed material pre-formed as pellets or as a mash.
- It is also possible to include the enzyme in the animal's diet by incorporating it into a second (and different) feed or drinking water which the animal also has access to. Accordingly, it is not essential that the enzyme is incorporated into the feed itself, although such incorporation forms a particularly preferred aspect of the present invention.
- If the enzyme is incorporated into a feed, then this preferably comprises at least 25% by weight of a cereal, and more preferably at least 35% by weight of the cereal. The cereal may be any one or more of wheat, maize, rye, barley, oats, triticale, rice, and sorghum. It is particularly preferred that the cereal is wheat.
- Although the cereal component of a cereal-based diet constitutes a source of protein, it is usually necessary to include sources of supplementary protein in the diet, such as those derived from fishmeal, meatmeal or vegetables. These sources of supplementary protein may constitute up to 50% by weight of the animal feed. Sources of vegetable protein include at least one of full fat soybean, rapeseed, canola, soybean meal, rapeseed meal and canola meal.
- If the enzyme is incorporated into a feed, then this is preferably added in a relative amount of 0.0001-10 g of the enzyme per kilo of the feed, more preferably 0.001-1 g/kg and most preferably 0.01-0.1 g/kg.
- The xylanase for use in this invention can be obtained from a fungus, such as Trichoderma, Aspergillus, Humicola, or Neocallimastix. Alternatively, the xylanase can be obtained from a bacterium, such as Bacillus, Streptomyces, Clostridium, or Ruminococcus.
- The present invention is particularly effective against strains of Salmonella and Campylobacter, and especially Salmonella enteritidis and Campylobacter jejuni. Another bacterium against which the invention is effective is Clostridium perfringens.
- Bacterial infection can be treated or prevented in accordance with the present invention in a wide variety of animals, but use of the invention is particularly preferred in domestic animals and farm livestock. Animals which may in particular benefit from the invention include poultry (such as chickens, turkeys, ducks and geese), ruminants (such as cattle, horses and sheep), swine (pigs), cats, dogs, rodents (such as rabbits) and fish. The invention is particularly useful in broiler chickens.
- The most preferred combinations of feed and enzyme include wheat plus xylanase, maize plus xylanase and barley plus β-glucanase.
- The enzymes used in the present invention fall within a general Class called polysaccharidases. Their substrates are structural polysaccharides such as xylans and β-glucans that occur as an integral part of the cell wall of most land plants. These polysaccharides are not found in animal cells, and are not to be expected to have any activity against proteins. Because these enzymes attack polysaccharides found in plant cell walls, the only possible substrates for these enzymes in the gastrointestinal tract of an animal are contained in cereal-based feeds. It is therefore speculated that the beneficial effects of the xylanase or cellulase on bacterial infection result somehow from the degradation products which they produce such as xylan or β-glucan derived from a cereal-based diet.
- As previously mentioned, WO 93/01800 discloses the use of a protease for the preparation of a medicament effective against intestinal pathogens in animals. It is well established that such pathogens mediate their infectivity by binding to receptors on the surface of intestinal epithelial cells via antigenic protein or glycoprotein molecules expressed on the pathogen's cell surface. It is suggested that the protease enzyme prevents binding of the pathogen cells to the intestinal epithelium by destroying these proteinaceous receptor/adhesion sites to which the pathogen must bind if it is to cause an infection. The protease ensymes mentioned in this reference would be predicted to destroy proteins on the lumenal surface of intestinal epithelial cells in a non-specific manner, but would not be expected to attack substrates other than proteins. Accordingly, the activity of the proteases disclosed in this reference is fundamentally different from the activity of the enzymes used in the present invention. A skilled person could not have predicted the utility of the present enzymes against bacterial infection based upon the activity of proteases disclosed in WO 93/01800.
- The invention will now be described in more detail according to the following Examples.
- Wheat and maize diets were prepared having the following formulations:
TABLE 1 Wheat diet Ingredients Percent Soft Wheat 58.83 Soybean ml 48 32.49 Soy oil 4.49 Salt 0.30 Sodium Bicarbonate 0.12 DL Methionine 0.14 Limestone 1.37 Di-calcium Phosphate 1.26 Vitamins/Minerals 1.00 TOTAL 100.00 -
TABLE 2 Maize diet Ingredients Percent Maize 58.38 Soybean ml 48 37.30 Soy oil 2.96 Salt 0.30 Sodium Bicarbonate 0.16 DL Methionine 0.13 Limestone 1.22 Di-calcium Phosphate 1.55 Vitamins/Minerals 1.00 TOTAL 100.00 - Animal feeds were prepared by introducing a cereal carrier containing approximately 3 mg enzyme protein/kg into the wheat diet at a concentration of 1 kg of enzyme and carrier per tonne of wheat diet. The final concentration of enzyme protein in the feed was thus approximately 3 mg per tonne. The xylanase was obtained from Trichoderma longibrachiatum. Broiler chicks were fed the wheat plus xylanase diet from hatching. For comparison purposes, separate flocks of chicks were fed with the wheat diet and the maize diet without the addition of xylanase. A challenge model was used, whereby 0.2 ml of a stock solution of C. jejuni were introduced to each chick by syringe at
day 7 from hatching. The dilution level of the stock solution was varied, from 10−1 (high challenge) to 10−6 (low challenge, similar to natural conditions). The undiluted stock solution contained approximately 104 CFU per 0.2 ml. The caecae of the chicks were examined for damage due to the Campylobacter at varying ages. -
FIGS. 1-6 show the effect of the diets on Campylobacter colonisation in 12-day old chicks. In each case two flocks, A and B, were tested to minimise the effect of environmental variance on the results. In each case it is clearly evident that a wheat plus xylanase diet is effective in reducing the level of Campylobacter in the caecae of the chicks in comparison with a maize diet. Additionally, at Campylobacter stock solution dilution levels of 10−3 or lower (i.e. approaching more natural conditions), the wheat plus xylanase diet becomes considerably more effective than the wheat diet alone. Thus, inFIG. 1 , for the wheat plus xylanase diet at a Campylobacter stock solution dilution of 10−6, a mean score of 0.5 positive caecae was observed. The equivalent scores for diets lacking xylanase were approximately 1.5 and 2.5. -
FIGS. 7-9 demonstrate the effectiveness of the diets on Campylobacter colonisation of the small intestine and caecae of 17-day old chicks from two flocks. The effect of the wheat plus xylanase diet on reducing the Campylobacter colonisation of the caecae of the chicks is evident as already demonstrated in Example 1. However this reduction is even more marked as regards the small intestine. Accordingly, inFIG. 7 the mean count log10CFU in the small intestine measured for chicks on the wheat and xylanase diet was less than 4. The equivalent counts for the diets not containing xylanase were found to be approximately 6, i.e. 100-fold higher. -
FIGS. 10-12 depict a comparison of the effect of different diets on the weight of 1, 5, 12, 19, 25 and 33-day old chicks.FIG. 10 shows the results for the wheat-based diet,FIG. 11 the results for the wheat plus xylanase-based diet andFIG. 12 the results for the maize-based diet. The weight of the chicks in each case is reduced by dosing with Campylobacter. However, those chicks to which Campylobacter has been introduced gain weight more quickly on the wheat plus xylanase diet than on either of the other diets. -
FIG. 13 demonstrates the effectiveness of the wheat and wheat plus xylanase diets on Salmonella enteritidis colonisation of the caecae of 14-day old chicks from two flocks, A and B. The methodology employed in these experiments was identical to that employed for the Campylobacter experiments described above, except that the undiluted stock solution of Salmonella enteritidis contained approximately 105 CFU per 0.2 ml. The effect of the wheat plus xylanase diet on reducing the Salmonella colonisation of the caecae of the chicks is clearly evident. Thus, in flock B, the chicks on the wheat diet were found to have a mean count log10CFU/ml of approximately 7. However, the chicks from flock B on the wheat plus xylanase diet were found to have a much lower log10CFU/ml of approximately 4 (1000-fold lower). - The above Examples clearly show a reduction in bacterial infection in the gut due to the inclusion of xylanase in the diet. Similar results have been observed when using a cellulase such as a β-glucanase. This indicates that the use provided by the present invention significantly reduces the ability of certain bacteria to colonise the caecae which in turn prevents migration of the bacteria to the small intestine. Accordingly, since it has a reduced level of infection, the growth rate of the animal is increased, leading to economic benefits. The reduction in contamination rate also has obvious benefits to human health and the replacement of antibiotics by such diets has clear environmental benefits.
Claims (16)
1. A method for treatment of a bacterial infection in chickens having bacterial infection in the absence of therapeutic or prophylactic amounts of antimicrobial drugs, the bacterial infection caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof, the method comprising:
feeding the chickens a diet comprising a feed including a cellulase and at least about 25% by weight of a cereal selected from the group consisting of wheat, maize, rye, barley, oats, triticale, rice, sorghum and mixtures thereof, the diet being effective for treatment of bacterial infection in the chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof, and the cellulase being present in an amount effective for treatment of the bacterial infection in the absence of an antimicrobial drug or in the presence of an antimicrobial drug at a concentration that in the absence of the cellulase is not effective for treatment of bacterial infection in chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof, and the diet not containing an antimicrobial drug or containing an antimicrobial drug at a concentration that is not effective in the absence of the cellulase for treatment of bacterial infection in chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof.
2. The method according to claim 1 wherein the cellulase is fed to the chickens in an amount of about 0.0001 to about 10 grams of cellulase per kg of the feed.
3. The method according to claim 1 wherein the cellulase is fed to the chickens in an amount of about 0.001 to about 1 gram of cellulase per kg of the feed.
4. The method according to claim 1 wherein the cellulase is fed to the chickens in an amount of about 0.01 to about 0.1 gram of cellulase per kg of the feed.
5. The method according to claim 1 wherein the cereal is wheat.
6. The method according to claim 1 wherein the cellulase is β-glucanase.
7. The method according to claim 6 wherein the cereal comprises wheat.
8. The method according to claim 1 wherein the diet is fed to the chickens without a withdrawal period prior to slaughtering of the chickens.
9. The method according to claim 1 wherein said diet does not contain an antimicrobial drug.
10. The method according to claim 1 wherein said diet contains an antimicrobial drug at a concentration that is not effective for treatment and/or prophylaxis of bacterial infection in chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof in the absence of the cellulase.
11. The method according to claim 8 wherein said diet does not contain an antimicrobial drug.
12. The method according to claim 8 wherein said diet contains an antimicrobial drug at a concentration that is not effective for treatment and/or prophylaxis of bacterial infection in chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof in the absence of the cellulase.
13. A method for treating a bacterial infection in a chicken caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof, the method comprising:
feeding the chicken an animal feed which comprises a cellulase and at least about 25% by weight of a cereal selected from the group consisting of wheat, maize, rye, barley, oats, triticale, rice, sorghum and mixtures thereof, the cellulase being included in the animal feed in an amount effective for treating the bacterial infection.
14. The method according to claim 13 wherein the cereal comprises wheat.
15. The method according to claim 13 wherein the cellulase is β-glucanase.
16. The method according to claim 15 wherein the cereal comprises wheat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/289,364 US20060083731A1 (en) | 1997-07-18 | 2005-11-30 | Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9715214A GB2327345B (en) | 1997-07-18 | 1997-07-18 | Use of an enzyme for manufacturing an agent for controlling bacterial infection |
| GBGB/9715214.4 | 1997-07-18 | ||
| PCT/EP1998/004440 WO1999003497A1 (en) | 1997-07-18 | 1998-07-16 | Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
| US09/487,383 US7011964B2 (en) | 1997-07-18 | 2000-01-18 | Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
| US11/289,364 US20060083731A1 (en) | 1997-07-18 | 2005-11-30 | Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/487,383 Division US7011964B2 (en) | 1997-07-18 | 2000-01-18 | Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20060083731A1 true US20060083731A1 (en) | 2006-04-20 |
Family
ID=10816111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/487,383 Expired - Fee Related US7011964B2 (en) | 1997-07-18 | 2000-01-18 | Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
| US11/289,364 Abandoned US20060083731A1 (en) | 1997-07-18 | 2005-11-30 | Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/487,383 Expired - Fee Related US7011964B2 (en) | 1997-07-18 | 2000-01-18 | Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7011964B2 (en) |
| EP (1) | EP0999851B1 (en) |
| JP (1) | JP2001510167A (en) |
| KR (1) | KR20010021993A (en) |
| AT (1) | ATE210457T1 (en) |
| AU (1) | AU733314B2 (en) |
| BR (1) | BR9810603A (en) |
| CA (1) | CA2296356A1 (en) |
| DE (1) | DE69802938T2 (en) |
| DK (1) | DK0999851T3 (en) |
| ES (1) | ES2169924T3 (en) |
| GB (1) | GB2327345B (en) |
| PL (1) | PL342188A1 (en) |
| PT (1) | PT999851E (en) |
| WO (1) | WO1999003497A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2444413A1 (en) | 2006-08-04 | 2012-04-25 | Verenium Corporation | Methods for oil or gas well drilling, washing and/or fracturing |
| WO2014207435A1 (en) | 2013-06-25 | 2014-12-31 | Ucl Business Plc | Anti-microbial agents and uses therefor |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR184500A0 (en) * | 2000-12-01 | 2001-01-04 | Drug Delivery Solutions Pty Ltd | Dispensing device |
| CN100391357C (en) * | 2002-02-26 | 2008-06-04 | 东莞市豪发生物工程开发有限公司 | Preparation of probiotics and compound enzyme feed additives by mixed fermentation of bacteria and fungi |
| EP1516053B1 (en) | 2002-06-14 | 2012-10-17 | Verenium Corporation | Xylanases, nucleic adics encoding them and methods for making and using them |
| AU2004254640B2 (en) | 2003-07-02 | 2010-08-26 | Bp Corporation North America Inc. | Glucanases, nucleic acids encoding them and methods for making and using them |
| CN102293323A (en) * | 2005-12-15 | 2011-12-28 | 坎姆根公司 | Enzymes for reduced immunological stress |
| EP2548956A1 (en) | 2006-02-14 | 2013-01-23 | Verenium Corporation | Xylanases, nucleic acids encoding them and methods for making and using them |
| AU2008307371B2 (en) | 2007-10-03 | 2015-05-28 | Bp Corporation North America Inc. | Xylanases, nucleic acids encoding them and methods for making and using them |
| DK2254591T3 (en) * | 2008-02-08 | 2017-11-06 | Prothera Inc | Inhibition or treatment of gastrointestinal biofilm |
| EP4371567A4 (en) * | 2021-07-14 | 2025-05-28 | Amano Enzyme Inc. | Agent for improving intestinal bacterial flora |
| CN118266495A (en) * | 2024-05-24 | 2024-07-02 | 中国农业科学院北京畜牧兽医研究所 | Complex enzyme system for killing salmonella and application thereof |
| CN118252181A (en) * | 2024-05-30 | 2024-06-28 | 中国农业科学院北京畜牧兽医研究所 | A composite enzyme system for killing salmonella and its application |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124262A (en) * | 1990-02-28 | 1992-06-23 | Amano Pharmaceutical Co., Ltd. | Mannose isomerase and process for mannose production using it |
| US5314692A (en) * | 1987-08-24 | 1994-05-24 | Cultor Ltd. | Enzyme premix for feed and method |
| US5470725A (en) * | 1989-02-16 | 1995-11-28 | Carlsberg A/S | Thermostable (1,3-1,4)-β-glucanase |
| US5612055A (en) * | 1994-08-19 | 1997-03-18 | Genecor International, Inc. | Enzyme feed additive and animal feed |
| US5624678A (en) * | 1994-05-10 | 1997-04-29 | Finnfeeds International Limited | Method and composition for treatment and/or prophylaxis of coccidiosis |
| US5817500A (en) * | 1995-01-26 | 1998-10-06 | Novo Nordisk A/S | Animal feed additives |
| US5902581A (en) * | 1995-12-04 | 1999-05-11 | Genencor International, Inc. | Xylanase from acidothermus cellulolyticus |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2321283A1 (en) * | 1975-05-14 | 1977-03-18 | Parcor | NEW DRUG WITH ANTIBACTERIAL ACTIVITY |
| FR2448351A1 (en) * | 1979-02-09 | 1980-09-05 | Brisou Jean | Compsns. contg. hyaluronidase, pectinase and bacitracine - cause bacterial detachment and render them more susceptible to antiseptics etc. |
| CA1321962C (en) * | 1985-03-20 | 1993-09-07 | Aizo Matsushiro | Dental caries preventive preparations and method for preparing said preparations |
| JPH06511237A (en) | 1991-07-24 | 1994-12-15 | コ、トーマス サイ イーング | Therapeutic composition and method for producing the same |
| GB2261877A (en) * | 1991-11-21 | 1993-06-02 | Kyowa Hakko Kogyo Kk | Animal feed additive comprising enzyme and amino acid |
| GB9200891D0 (en) * | 1992-01-16 | 1992-03-11 | Mann Stephen P | Formulation of microorganisms |
| GB9406317D0 (en) * | 1994-03-30 | 1994-05-25 | Finnfeeds Int Ltd | Use of an enzyme for assisting an animal to digest protein |
| AUPN033894A0 (en) * | 1994-12-29 | 1995-01-27 | Rowe, J.B. | Prevention of adverse behaviour in humans and animals |
| JPH0984529A (en) * | 1995-09-27 | 1997-03-31 | Kohjin Co Ltd | Cattle and poultry feed containing mannan originated from microorganism |
| SE510498C2 (en) * | 1996-02-14 | 1999-05-31 | Biofeed Thailand Co Ltd | Animal feed additive containing microorganisms |
| AU2381097A (en) * | 1996-04-16 | 1997-11-07 | Novo Nordisk A/S | Compositions for the removal of dental plaque |
-
1997
- 1997-07-18 GB GB9715214A patent/GB2327345B/en not_active Expired - Fee Related
-
1998
- 1998-07-16 BR BR9810603-1A patent/BR9810603A/en not_active Application Discontinuation
- 1998-07-16 ES ES98940239T patent/ES2169924T3/en not_active Expired - Lifetime
- 1998-07-16 KR KR1020007000560A patent/KR20010021993A/en not_active Withdrawn
- 1998-07-16 CA CA002296356A patent/CA2296356A1/en not_active Abandoned
- 1998-07-16 PL PL98342188A patent/PL342188A1/en unknown
- 1998-07-16 AT AT98940239T patent/ATE210457T1/en not_active IP Right Cessation
- 1998-07-16 EP EP98940239A patent/EP0999851B1/en not_active Expired - Lifetime
- 1998-07-16 DK DK98940239T patent/DK0999851T3/en active
- 1998-07-16 PT PT98940239T patent/PT999851E/en unknown
- 1998-07-16 DE DE69802938T patent/DE69802938T2/en not_active Expired - Fee Related
- 1998-07-16 AU AU88623/98A patent/AU733314B2/en not_active Ceased
- 1998-07-16 WO PCT/EP1998/004440 patent/WO1999003497A1/en not_active Ceased
- 1998-07-16 JP JP2000502793A patent/JP2001510167A/en not_active Withdrawn
-
2000
- 2000-01-18 US US09/487,383 patent/US7011964B2/en not_active Expired - Fee Related
-
2005
- 2005-11-30 US US11/289,364 patent/US20060083731A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314692A (en) * | 1987-08-24 | 1994-05-24 | Cultor Ltd. | Enzyme premix for feed and method |
| US5470725A (en) * | 1989-02-16 | 1995-11-28 | Carlsberg A/S | Thermostable (1,3-1,4)-β-glucanase |
| US5124262A (en) * | 1990-02-28 | 1992-06-23 | Amano Pharmaceutical Co., Ltd. | Mannose isomerase and process for mannose production using it |
| US5624678A (en) * | 1994-05-10 | 1997-04-29 | Finnfeeds International Limited | Method and composition for treatment and/or prophylaxis of coccidiosis |
| US5612055A (en) * | 1994-08-19 | 1997-03-18 | Genecor International, Inc. | Enzyme feed additive and animal feed |
| US5817500A (en) * | 1995-01-26 | 1998-10-06 | Novo Nordisk A/S | Animal feed additives |
| US5902581A (en) * | 1995-12-04 | 1999-05-11 | Genencor International, Inc. | Xylanase from acidothermus cellulolyticus |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2444413A1 (en) | 2006-08-04 | 2012-04-25 | Verenium Corporation | Methods for oil or gas well drilling, washing and/or fracturing |
| WO2014207435A1 (en) | 2013-06-25 | 2014-12-31 | Ucl Business Plc | Anti-microbial agents and uses therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| PL342188A1 (en) | 2001-05-21 |
| DE69802938D1 (en) | 2002-01-24 |
| PT999851E (en) | 2002-05-31 |
| DE69802938T2 (en) | 2002-08-14 |
| ES2169924T3 (en) | 2002-07-16 |
| JP2001510167A (en) | 2001-07-31 |
| GB2327345B (en) | 1999-06-23 |
| GB2327345A (en) | 1999-01-27 |
| EP0999851A1 (en) | 2000-05-17 |
| US7011964B2 (en) | 2006-03-14 |
| US20010046494A1 (en) | 2001-11-29 |
| KR20010021993A (en) | 2001-03-15 |
| AU8862398A (en) | 1999-02-10 |
| EP0999851B1 (en) | 2001-12-12 |
| ATE210457T1 (en) | 2001-12-15 |
| BR9810603A (en) | 2000-07-11 |
| WO1999003497A1 (en) | 1999-01-28 |
| AU733314B2 (en) | 2001-05-10 |
| CA2296356A1 (en) | 1999-01-28 |
| DK0999851T3 (en) | 2002-04-08 |
| GB9715214D0 (en) | 1997-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2498143C (en) | Antimicrobial composition and method for use | |
| Hajati | Application of organic acids in poultry nutrition | |
| Salim et al. | Global restriction of using antibiotic growth promoters and alternative strategies in poultry production | |
| US7014863B2 (en) | Additive for an animal feed | |
| KR20130108664A (en) | Compositions and methods for controlling disease in animals | |
| US7011964B2 (en) | Use of an enzyme for the manufacture of an agent for controlling bacterial infection | |
| KR19990082623A (en) | Animal feed | |
| Wang et al. | Effects of flavomycin, Bacillus licheniformis and enramycin on performance, nutrient digestibility, gut morphology and the intestinal microflora of broilers | |
| US5624678A (en) | Method and composition for treatment and/or prophylaxis of coccidiosis | |
| Flammer | Treatment of chlamydiosis in exotic birds in the United States | |
| MXPA00000614A (en) | Use of an enzyme for the manufacture of an agent for controlling bacterial infection | |
| McKean | Feed additives for swine | |
| Khattak et al. | Enzymes in Poultry: A Review | |
| Gawande et al. | Feed hygiene protects animals and humans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |